Showing 4531-4540 of 8732 results for "".
- Aldeyra Therapeutics' Lead Candidate NS2 Shows Novel Approach to Treating Dry Skin, Eye Diseaseshttps://practicaldermatology.com/news/20140512-aldeyra_therapeutics_lead_candidate_ns2_shows_novel_approach_to_treating_dry_skin_eye_diseases/2459242/Aldeyra Therapeutics' lead candidate NS2 decreases aldehyde levels in dry skin and eye models, according to data to be presented as an abstract poster at the Society for Investigative Dermatology (SID) 2014 Annual Meeting, in Albuquerque, NM. The study found that topical applicat
- Researchers Examine UV Nail Salon Lamps and Risk of Skin Cancerhttps://practicaldermatology.com/news/20140501-researchers_examine_uv_nail_salon_lamps_and_risk_of_skin_cancer/2459249/A recent research letter in JAMA Dermatology stated that although using higher-wattage ultra violet (UV) lamps at nail salons to dry and c
- Survey Finds Rosacea Sufferers' More Likely to be Judged Negatively Upon First Impressionhttps://practicaldermatology.com/news/20140428-survey_finds__rosacea_sufferers_more_likely_to_be_judged_negatively_upon_first_impression/2459251/A new survey by the National Rosacea Society finds that rosacea sufferers' are often judged negatively upon first impression. Shy, nervous, and stressed are the three words respondents used to describe their view of an individual with redness on their face, without knowing anything about them.
- Novan Therapeutics to Present Data at 2014 Society for Investigative Dermatology Annual Meetinghttps://practicaldermatology.com/news/20140425-novan_therapeutics_to_present_data_at_2014_society_for_investigative_dermatology_annual_meeting/2459255/Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, will present data from the Phase 2 clinical trial in acne vulgaris with its lead product candidate, SB204, at the 2014 Annual Meeting of the Society for Investigative Dermatol
- ALPHAEON Launches New Patient Financing Solutionhttps://practicaldermatology.com/news/20140425-alphaeon_launches_new_patient_financing_solution/2459256/ALPHAEON Corporation, a subsidiary of Strathspey Crown Holdings, LLC, launched ALPHAEON CREDIT, which the company describes as a new tool for patients seeking to finance self-pay lifestyle healthcare procedures through board-certified specialty physicians in dermatology, ophthalmology, plast
- Nuvo Research Announces Collaboration to Develop Topical Dermatology Productshttps://practicaldermatology.com/news/20140423-nuvo_research_announces_collaboration_to_develop_topical_dermatology_products/2459258/Nuvo Research Inc. is collaborating with Ferndale Laboratories, Inc. and a leading Contract Research Organization (CRO) with significant dermatology experience to develop two topical dermatology products based on Nuvo's patented Multiplexe
- Innocutis Introduces Dexter the Dystrophic Nail to Educate Patientshttps://practicaldermatology.com/news/20140417-innocutis_introduces_dexter_the_dystrophic_nail_to_educate_patients/2459265/Innocutis launched an animated social media campaign to educate on the prevalence of nail dystrophy and Nuvail as a viable treatment option. The antagonist of healthy nails in what the company calls a “fun, light-hearted, social media campaign” is
- bioskin Continues US Expansion with Launch of New Websitehttps://practicaldermatology.com/news/20140417-bioskin_continues_us_expansion_with_launch_of_new_website/2459268/bioskin® follows expansion of its US office, spearheaded by AJ Acker, Executive Director of Global Regulatory and Clinical Affairs, with the launch of our a website www.bioskinCRO.com. The new layout was designed with ease of u
- Mirvaso Now Available in the UKhttps://practicaldermatology.com/news/20140417-mirvaso_now_available_in_the_uk/2459269/Mirvaso (brimonidine) 3mg/g gel, an alpha-2 adrenergic agonist indicated for the symptomatic treatment facial erythema associated with rosacea in adult patients, is now available in the UK. The active ingredient, brimonidine, restricts excessive blood f
- Lithera to Present at the 13th Annual Needham Healthcare Conferencehttps://practicaldermatology.com/news/20140402-lithera_to_present_at_the_13th_annual_needham_healthcare_conference/2459280/Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, today announced that George Mahaffey, President and Chief Executive Officer, will present at the 13th Annual Needham Healthcare Conference on Wednesday, April